1. Home
  2. AHG vs SGP Comparison

AHG vs SGP Comparison

Compare AHG & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHG

Akso Health Group ADS

HOLD

Current Price

$1.44

Market Cap

757.9M

ML Signal

HOLD

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$27.59

Market Cap

835.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AHG
SGP
Founded
2013
2019
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
757.9M
835.4M
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
AHG
SGP
Price
$1.44
$27.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.7K
385.5K
Earning Date
08-14-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,842,253.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
512.09
N/A
52 Week Low
$0.83
$20.16
52 Week High
$2.10
$32.44

Technical Indicators

Market Signals
Indicator
AHG
SGP
Relative Strength Index (RSI) 48.25 N/A
Support Level $1.37 N/A
Resistance Level $1.48 N/A
Average True Range (ATR) 0.12 0.00
MACD -0.01 0.00
Stochastic Oscillator 40.70 0.00

Price Performance

Historical Comparison
AHG
SGP

About AHG Akso Health Group ADS

Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: